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Abstract. Previous studies have failed to reach consensus on insulin levels in cerebrospinal fluid of Alzheimer’s disease (AD)
patients and on its relation to pathological features. We performed a new analysis in patients at different stages of AD, and
investigated the relationship of insulin levels with biochemical disease markers and with cognitive score. We included 99 patients
from our Memory Clinic (Karolinska University Hospital, Sweden), including: 27 patients with mild AD, 13 that progressed
from mild cognitive impairment (MCI) to AD in two years time, 26 with MCI stable after two years, and 33 with subjective
cognitive impairment. Insulin was significantly decreased in the cerebrospinal fluid of both women and men with mild AD.
Insulin deficits were seen in women belonging to both MCI groups, suggesting that this occurs earlier than in men. Insulin was
positively associated with amyloid-β 1-42 (Aβ1−42) levels and cognitive score. Furthermore, total-tau/(Aβ1−42*insulin) ratio
showed strikingly better sensitivity and specificity than the total-tau/Aβ1−42 ratio for early AD diagnosis in women.
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INTRODUCTION
The functions of insulin governing peripheral glu-
cose homeostasis and its involvement in diabetes mel-
litus are well known. However, less is known about
the roles of insulin beyond the periphery, in the cen-
tral nervous system (CNS). Insulin receptors are found
throughout the CNS, although it is unclear whether
brain insulin comes only from the blood through the
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blood-brain barrier (BBB) [1] or is also synthesized by
CNS cells [2,3]. Insulin participates in a number of
brain functions, such as regulation of food intake and
body weight [4], and in cognition by modulating synap-
tic plasticity and long-term potentiation [5,6]. Diabetes
mellitus type 2, which is mainly associated with insulin
resistance, is a risk factor for dementia and AD [7].
Evidence of insulin resistance in AD is suggested
by reports of reduced glucose utilization and deficient
energy metabolism in early stages of the disease [8,9].
Expression of insulin, insulin-like growth factor (IGF)-
I and -II, as well as their receptors, was found to be in-
creasingly down-regulated in postmortem brain tissue
of AD patients, in correspondence with the severity of
the disease [2,3]. In vitro and in vivo animal studies fur-
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ther support the association of insulin with the classical
pathogenic hallmarks of AD, namely amyloid protein
precursor (AβPP)/amyloid-β(Aβ) and tau [10–12].
The possible association of brain insulin levels with
AD pathogenesis needs to be assessed at all stages dur-
ing the course of the disease. Cerebrospinal fluid (CSF)
measurements can be used to investigate all stages,even
the earliest ones. Three studies have, so far, investigat-
ed CSF-insulin levels in AD. Craft et al. reported de-
creased CSF-insulin in advanced AD [13]. In contrast,
the two other studies showed increased levels [14] or no
changes [15]. None of these studies found correlations
found between insulin levels and pathological features
or the cognitive status of AD patients.
The present study aims to further clarify the meaning
of CSF-insulin levels in AD. We have investigated CSF-
insulin levels in memory clinic patients with mild-AD,
subjective cognitive impairment (SCI), and in the state
considered relatively high-risk for AD [16], mild cog-
nitive impairment (MCI). Moreover, we have divided
the MCI group into those who progressed to AD in two
years time, and those who did not in this time frame-
work. The questions addressed in this paper include:
a) Are CSF-insulin levels abnormal in AD or MCI?;
b) Is gender or apolipoprotein E (ApoE) genotype dif-
ferentially affecting CSF-insulin in AD or MCI?; c) Is
insulin associated to some AD hallmark?; and d) Does
insulin has prognostic value for early diagnosis?
METHODS
Study population
The patients included in the study (n = 99) were
from the Memory Clinic at the Karolinska Universi-
ty Hospital in Huddinge, Sweden: 33 had subjective
cognitive impairment (SCI), 39 MCI, and 27 mild-AD.
In the MCI group, 13 had progression-to-AD (PMCI)
within two years time, and 26 remaining stable (SMCI).
These patients were all living independently in the com-
munity. They were evaluated according to a standard
comprehensive assessment protocol including clinical
examination, brain imaging, electroencephalography,
analyses of blood (serum albumin, glucose) and CSF
(including albumin, total tau (T-tau), phospho-tau (P-
tau), and Aβ1−42) and a detailed neuropsychological
evaluation. Dementia and AD were diagnosed accord-
ing to DSM-IV and NINCDS-ADRDA criteria. MCI
patients were (1) not demented, (2) had (self and/or an
informant) reported cognitive decline and impairment
on objective cognitive tasks, and (3) had preserved ba-
sic ADL/minimal impairment in complex instrumental
functions. SCI patients had cognitive complaints with-
out impairment on objective cognitive tasks. Women
under hormonal replacement therapy, as well as pa-
tients with psychiatric disorders (i.e., depression, alco-
hol abuse) or other conditions (i.e., diabetes, brain tu-
mors, normal pressure hydrocephalus) were not includ-
ed. The study was conducted under the guidelines of
the Declaration of Helsinki and approved by the ethics
committee of the Karolinska Institutet.
CSF measurements
CSF was collected for diagnostic purpose by lumbar
puncture as previously described [17,18]. CSF samples
were obtained by lumbar puncture performed in the sit-
ting position. CSF extraction is routinely performed
at the Karolinska University Hospital Memory clinic
in Huddinge (Sweden) as part of the medical examina-
tion. The extractions were performed in the mornings
in fasting patients. CSF samples were obtained from
L3/L4 or L4/L5 interspaces after local anesthetic infil-
tration in the skin. After disposal of the first ml. the
following 10 ml were collected in polypropylene tubes.
No sample contained more than 500 erythrocytes/µl
CSF samples was used. Samples were gently mixed to
avoid gradient effects and centrifuged at 2000×g for 10
min to eliminate cells and insoluble material. Super-
natants were aliquoted, immediately frozen and stored
at −80◦C pending biochemical analyses. Tau was de-
termined using a sandwich enzyme-linked immunoab-
sorbent assay (ELISA) [19]. P-tau (P-Thr181) was de-
termined using a sandwich ELISA, with monoclonal
antibody HT7 (recognizing all forms of tau) used as
capturing antibody, and AT270 (specific to P(Thr181)-
tau) used as a detection antibody [20]. Aβ1−42was
determined using a sandwich ELISA as previously de-
scribed [18]. All kits were purchased from Innogenet-
ics NV, Ghent, Belgium. Insulin levels were measured
by a highly sensitive radioenzymatic assay, using Ul-
tra Sensitive Human Insulin RIA kit (Linco Research.
HI-11K).
Data analysis
Normal distribution of data was checked by Shapiro-
Wilks. Analytics are presented as mean values± stan-
dard error mean (SEM). Linear regression was used to
analyze the association of CSF-insulin levels with age,
BMI and plasma glucose levels. Insulin levels were
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Table 1
Demographic and clinical characteristics of participants
SCI SMCI MCI-AD Mild-AD
Demographics
n 33 26 13 27
Gender (male/female) 14/19 17/9 4/9 8/19
Age (years) 57.5 (1.1) 61.6 (2.0) 63.1 (2.3) 68.6 (1.8)a,b
Education (years) 14 (0.6) 12.4 (0.7) 14 (1.1) 9.7 (0.6)a,b,c
ApoE4 carriers (%) 39 50 84 70
MMSE (points) 29.1 (0.2) 28.3 (0.3) 27.5 (0.3)a 23.6 (0.7)a,b’,c
Clinical data
Body mass index (kg/m2) 25.1 (0.7) 26.3 (1.1) 22.2 (0.8)b 22.9 (0.9)b
Fasting plasma glucose 5.4 (0.9) 5.5 (1.1) 5.1 (0.8) 5.5 (0.9)
AlbCSF /Albserum 5.9 (0.4) 6.6 (0.6) 5.5 (0.8) 6.8 (0.5)
CSF Aβ1−42(ng/L) 844.9 (29.0) 677.9 (45.2)a 420.2 (28.8)a,b’ 468.9 (26.9)a,b’,c
CSF T-tau (ng/L) 273.3 (20.2) 401.9 (110.8) 456.3 (64.7) 667.9 70.4)a,b
CSF P-tau (ng/L) 50.8 (3.4) 55.5 (7.8) 70.6 (12.5) 94.2 (8.2)a,b
Numeric values are presented as number of patients, percentage or mean (SEM).
SCI: subjective cognitive impairment; SMCI: stable mild-cognitive impairment; MCI-AD: mild cog-
nitive impairment with AD progression; AD: Alzheimer’s disease; MMSE: Mini-Mental State Exam-
ination; CSF: cerebrospinal fluid; Alb: albumin.
ap < 0.001 vs. SCI; bp < 0.05 vs. SMCI; b’p < 0.001 vs. SMCI; cp < 0.001 vs. PMCI.
analyzed using ANOVA after removing the variance
of the covariates gender and age (ANCOVA). Pairwise
comparisons were performed by HSD Tukey’s post-
hoc test. Associations between Aβ1−42, P-tau, severi-
ty of dementia (MMSE score), and insulin levels were
assessed by partial correlation analysis after correct-
ing for the grouping effect. Cut-off for sensitivity and
specificity and area under the curve (AUC) were derived
from receiver operating characteristic (ROC) curves.
Significance was defined as p 6 0.05. Analyses were
performed with SPSS 12.0 (SPPS, Chicago, USA) and
MedCalc 10.0.2 (MedCalc Software, Belgium).
RESULTS
General characteristics of the population
Demographic and clinical characteristics of study
participants are shown in Table 1. AD patients were
significantly older than SMCI and SCI (F(3,95) = 8.46;
p < 0.05 and p < 0.001, respectively). MMSE score
was lowest in AD patients (F(3.95) = 36.06,p < 0.001).
However, patients with PMCI had also a lower score
when compared to SCI (p < 0.001).
AD patients presented lower CSF levels of Aβ1−42,
and higher T-tau and P-tau when compared to either
SCI (F(3,82) = 18.14, p < 0.001; F(3,85) = 5.93, p <
0.001; F(3,73) = 8.72, p < 0.001, respectively) or SM-
CI patients (p < 0.05) after correcting for age. CSF-
Aβ1−42 levels of PMCI group were lower than SMCI
and SCI (p < 0.05 and p < 0.001, respectively).
Insulin is decreased in CSF of AD patients
Linear regression analysis did not show any signifi-
cant interaction between CSF levels of insulin and age
(R = 0.15, n = 80, p = 0.16), BMI (R = 0.11, n =
43, p = 0.48) or plasma glucose levels (R = 0.11,
n = 79, P = 0.33). A significant reduction (of ap-
proximately 22%) of CSF-insulin was found in patients
with mild-AD compared to SCI (0.414 ± 0.036 ver-
sus 0.566± 0.028 µU/mL, one-way ANOVA followed
by HSD Tukey’s test, F(3,72) = 3.22, p < 0.05). The
PMCI group tended to have decreased insulin levels,
although this was not statistically significant (0.480 ±
0.054 µU/mL; p = 0.19). Neither were significant dif-
ferences (p = 0.98) found between patients with SMCI
(0.548± 0.046 µU/Ml) and SCI (Fig. 1A).
Figure 1B shows the gender-stratified distribution
of CSF-insulin levels along the 4 diagnostic groups.
Women presented lower levels of CSF-insulin than
did men (0.487 ± 0.026 vs. 0.578 ± 0.036 µU/mL,
F(1,79) = 4.56, p < 0.05); and a significant interaction
between grouping and gender was found (F(3,79) =
2.65, p < 0.05, two-way ANOVA). No difference was
found between men (0.433± 0.034) and women (0.436
± 0.052) in the mild-AD group (p= 1.00, HSD Tukey’s
test). However, significantly lower CSF-insulin levels
were found in women from the SMCI group (0.615 ±
0.054 for men vs. 0.407 ± 0.057 µU/mL for wom-
en; p < 0.01, HSD Tukey’s test). Women with PM-
CI showed also a trend of reduction, although non-
significant with the number of individuals in the study,
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Fig. 1. CSF levels of insulin are decreased in mild-AD. A) Fasting CSF-insulin (µU/mL) with standard errors for the overall subjective cognitive
impairment (SCI), stable MCI (SMCI), MCI with AD progression (PMCI) and mild-AD. Mild-AD subjects showed significant lower levels of
CSF-insulin than SCI (p < 0.05). B) Fasting CSF-insulin (µU/mL) with standard errors for male (white columns) and female (black columns)
SCI, SMCI, PMCI and mild-AD groups. SMCI women showed reduced levels of CSF-insulin when compared to men of the same group (p <
0.05), and women from PMCI group presented the same trend of reduction by nearly reaching significance (p = 0.1).
when compared to men with PMCI (0.602 ± 0.069
versus 0.399 ± 0.058 µU/mL, p = 0.08, HSD Tukey’s
test).
Levels of CSF-insulin between apoE ε4-carriers and
non-carriers did not differ (0.513 ± 0.031 for ε4-
carriers vs. 0.547± 0.032 for ε4 non-carriers,Student’s
t(69) = 0.932, p = 0.36), and no interaction between
grouping and ApoE genotype was found (F(3,78) =
0.27, p = 0.85, two-way ANOVA) (Fig. 1C).
Insulin was also significantly and positively correlat-
ed to AlbuminCSF /Albuminserum ratio (Spearman’s
rho = 0.231, p < 0.05). Furthermore, this ratio was
lower in women than in men (5.26 ± 1.98 vs. 7.64 ±
2.81; F(1,98) = 22.01, p < 0.01, two-way ANOVA).
These differences were attributed to a significantly low-
er ratio in women both in SCI (4.95 ± 0.37 vs. 7.09 ±
0.73; p < 0.01, HSD Tukey’s test) and SMCI groups
(4.48 ± 0.59 vs. 7.81 ± 0.73; p < 0.05, HSD Tukey’s
test). Women from PMCI and AD showed a weaker
trend toward decrease when compared to men from the
same groups, although this was non-significant (4.82±
0.74 vs. 7.18 ± 1.67, p = 0.270; 6.85 ± 0.48 vs. 8.48
± 0.91, p = 0.122; respectively).
CSF-insulin levels correlate with CSF-Aβ1−42 among
women in the non-AD groups.
No correlation between overall CSF levels of insulin
and T-tau (r = − 0.06,n = 75, p = 0.31), P-tau (r = −
0.03, n = 65, p = 0.41), Aβ1−42 (r = 0.10, n = 70,
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p = 0.21) or MMSE (r = 0.21, n = 76, p = 0.09) was
found after correcting for grouping effect. However,
CSF-insulin levels among the women belonging to SCI
and SMCI groups (patients without AD or with no
conversion in 2 years time) were positively associated
to CSF-Aβ1−42 (r = 0.44, n = 19, p < 0.05; corrected
for grouping effect). This correlation was absent in
women from the PMCI and AD groups (r = − 0.15,
n = 20, p = 0.26).
Insulin improves the predictive accuracy of CSF
biomarkers tau and Aβ1−42 in women
Numerous studies have explored the use of the CSF
concentration of classical AD hallmarks as biomarkers
for an early diagnosis [21]. The ratio between T-tau and
Aβ1−42 levels has been proposed as the most sensitive
for diagnostic proposes [21]. In view of our results, we
next investigated if CSF-insulin could be an additional
AD biomarker in women. Both sensitivity and speci-
ficity of CSF T-tau/Aβ1−42 ratio, when distinguishing
PMCI and mild-AD from SCI and SMCI, were im-
proved in women after adding insulin to the equation
(T-tau/(Aβ1−42∗insulin) ratio), (see ROC analysis in
Fig. 2). The best cutoff level for T-tau/Aβ1−42 ra-
tio (0.700) resulted in a sensitivity of 87.5% (95% CI,
67.6 to 97.2%) and a specificity of 92.3% (95% CI,
74.8 to 98.8%) with an area under the curve (AUC)
of 0.918 ± 0.041, while the best cutoff level for T-
tau/(Aβ1−42∗insulin) ratio (1.182) resulted in a sensi-
tivity of 100.0% (95% CI, 82.2 to 100%) and a speci-
ficity of 95.0% (95% CI, 75.1 to 99.2%) with an AUC
of 0.995± 0.011.
DISCUSSION
This study reports lower CSF-insulin levels in pa-
tients with mild-AD compared to SCI. The decrease in
CSF-insulin was seen earlier during the disease course
in women, and was independent of the ApoE genotype.
In addition, we found that a combination of insulin,
Aβ1−42 and tau measurements in CSF was of great sen-
sitivity and specificity for distinguishing women that
have mild-AD (MMSE: 23.6) or that will develop AD
within two years time (PMCI), from other groups (SCI
and SMCI).
Central insulin signaling has become a focus of at-
tention in studying AD pathophysiology. Experimen-
tal data has revealed the importance of brain insulin in
controlling tau phosphorylation, protecting against Aβ
Fig. 2. Insulin improves sensitivity and specificity of classical
CSF-AD biomarkers in women. The plot shows a ROC curve analy-
sis for women from AD groups (PMCI and mild-AD) versus non-AD
groups (SCI and SMCI groups). The optimal cut-off value for
T-tau/Aβ1−42 ratio (open squares) was 0.700, resulting in a sensi-
tivity of 87.5%, a specificity of 92.3% and an AUC of 0.918. The
optimal cut-off value for T-tau/Aβ1−42*insulin ratio (filled circles)
was 1.182, resulting in a sensitivity of 100%, a specificity of 95%
and an AUC of 0.995.
accumulation and toxicity and in promoting synaptic
plasticity, neuronal growth and survival [22]. Epidemi-
ological studies have reported an association of insulin
resistance and its subsequent compensatory hyperinsu-
linemia with cognitive decline in elderly subjects [23,
24], and with a higher risk of developing AD [25,26].
However, most studies have focused on peripheral in-
sulin; studies on central insulin showing decreased ex-
pression of insulin and insulin receptor [2,3] have been
carried out in postmortem tissue. The present study
investigates central insulin in memory clinic patients
by measuring CSF levels at different stages of AD.
We found decreased levels of CSF-insulin in pa-
tients with mild-AD. Our results were significant even
after controlling for age and gender. These findings
are in agreement with previous studies reporting low-
er CSF-insulin in more advanced AD [13,27]. Two
other studies found either increased levels [14] or no
changes [15]. One possible explanation for these dis-
crepancies could be BBB integrity, which was not con-
sidered in previous reports [14,15]. Disruption of BBB
occurs in the later stages of AD [28], and a subsequent
leaking of insulin from blood to brain could explain the
finding of higher insulin levels in CSF. Interestingly,
increased plasma levels of insulin have been reported in
late AD [13,22,29]. The apparent discrepancy between
peripheral and central insulin in AD might be due to
down-regulation of insulin transport into the brain in
conditions of insulin resistance [30]. To the contrary,
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others have proposed that this discrepancy might be
due to an altered insulin production in the brain [2,3].
The local production of insulin in the brain, as well as
the factors that regulate the transport of peripheral in-
sulin into the brain, are largely unknown. The interplay
between the peripheral and central insulin productions
and homeostasis needs to be further investigated, since
it is of vital importance to understand the role of insulin
in neurodegenerative disorders like AD.
Previous reports have shown that non-homozygotes
for the ε4 allele had higher plasma insulin than ε4
carriers [13,27]. In the present study, no significant
differences in CSF-insulin were found between ApoE
ε4 carriers and non-carriers, although it is possible that
the number of samples in our study would limit the
detection of differences in ApoE subgroups.
We have not found an association between CSF-
insulin and cognitive status. Only one previous study
reporting changes in CSF-insulin showed its relation-
ship to MMSE score in later stages of the disease [13].
Also peripheral insulin has been found to be posi-
tively associated with cognition [23], and with plas-
ma Aβ1−42 in amnesic MCI and healthy individu-
als [31,32]. It has been shown that raising brain in-
sulin levels by intranasal insulin administration facili-
tates verbal memory, attention and functional status in
patients with early AD and in memory-impaired older
adults [33]. Raising brain insulin levels also improved
Aβ1−42 clearance to CSF in older adults [34].
The mechanisms by which insulin participates in
Aβ clearance are not fully understood. Tamaki
et al. reported that insulin induces expression of
low-density lipoprotein receptor-related protein (LRP-
1) [35]. LRP-1 is a key molecule in Aβ clearance from
the brain through the BBB [36], and probably through
CSF. Members of the LRP family have been found in
the choroid plexus [37].
Insulin was also shown in vitro to reduce the intra-
cellular accumulation of Aβ by accelerating AβPP/Aβ
trafficking from the trans-Golgi network to the plasma
membrane [12]. An insulin-mediated enhancement of
Aβ trafficking to extracellular compartments may also
contribute to a more effective clearance to the CSF.
In addition, a role for insulin in the regulation of
Aβ levels can be envisaged. Deficient insulin signal-
ing was correlated with reduced insulin degrading en-
zyme (IDE) in AD brains and in Tg2576 transgenic
animals [38]. IDE is not only a proteolytic degrading
enzyme for insulin but also for Aβ and a number of
other peptides [39].
We have found a positive association between CSF-
insulin and CSF-Aβ1−42 in women belonging to SCI
and SMCI groups. Why levels of CSF-insulin are asso-
ciated with levels of CSF-Aβ1−42, in these groups but
not in pre-AD or AD cases remains to be determined.
A possibility could be that brain insulin might favor Aβ
degradation/clearance to the CSF in non-pathological
conditions, while levels of both insulin and Aβ are bal-
anced. In AD, however, lower brain insulin levels co-
exist with Aβ overproduction. This imbalance could
result in deficient Aβ degradation/clearance and thus
in increased neuronal exposure to toxic Aβ species. If
this is the case, an induction of insulin in the brain could
be beneficial for AD patients.
We found that the decrease of CSF-insulin levels oc-
curred earlier in women than in men. In fact, wom-
en belonging to both MCI groups (SMCI and PM-
CI) showed lower CSF-insulin levels than did men.
This gender difference was not seen in mild-AD cases.
There is little data on gender differences in insulin lev-
els/function in AD, and no reports regarding AD pro-
gression. Female AD subjects have been shown to have
lower plasma insulin levels compared to males [27].
An interaction between some gonadal hormonal sys-
tem (that could be affected in post-menopausal wom-
en with AD) and brain insulin synthesis or degrada-
tion, could also be hypothesized. However, insulin,
like other peptides or regulatory proteins, is known to
cross the BBB by a saturable transport mechanism [1].
Thus, the correlation between CSF and serum levels of
insulin is non-linear; and the rate of increase in CSF
levels becomes proportionately smaller at higher serum
levels [40]. Indeed, the transport rate of insulin has
been shown to be altered in different conditions with
abundant peripheral insulin, such as obesity, diabetes
mellitus or insulin resistance [1]. A similar disruption
in insulin transport through the BBB has been previous-
ly proposed in AD [13], where the levels of insulin in
plasma are increased [13,22]. Thus, a decreased trans-
port of insulin from plasma to brain, due to saturation
of the insulin BBB transporter, could contribute to the
lower CSF-insulin levels in AD seen in our study.
Possible gender differences in BBB integrity could
be also of importance. BBB dysfunction is indeed a fea-
ture of AD [41], and gender differences are important in
BBB permeability under pathological conditions [42]
but not under normal conditions [43]. In line with this
hypothesis, BBB integrity has been shown to be pri-
marily affected in male AD patients [44]. In the present
study, the ratio between CSF and plasma levels of al-
bumin was used as an indicator of BBB integrity [28].
We show that albumin CSF-to-plasma ratio positive-
ly correlated to CSF-insulin, suggesting the possibili-
F.J. Gil-Bea et al. / Early CSF-Insulin Decrease in Women with AD 411
ty that increased uptake of albumin from periphery to
brain could be associated with higher infiltration of in-
sulin from plasma. Moreover, albumin CSF-to-plasma
ratio was reduced in women compared to men in both
MCI groups, indicating a gender-dependent disruption
of BBB integrity in early phases of AD. Thus, it is
tempting to speculate that men with MCI would show
higher CSF-insulin levels due to a higher uptake of
peripheral insulin, resulting from the degraded perfor-
mance of the BBB. However, in disagreement with this
hypothesis, we also found that later in the disease (mild-
AD) both genders had similar lowered CSF-insulin lev-
els and similarly disrupted BBB markers, compared to
controls.
In summary, why women have lower levels of CSF-
insulin at early stages of the disease is puzzling, and
the possibilities of hormonal dependent mechanisms
affecting insulin synthesis, transport or degradation, as
well as the contribution of gender differences in BBB
integrity should be further investigated.
The significant decrease in CSF-insulin levels seen
in women at early stages of AD led us to investigate the
relevant potential of using this parameter for early diag-
nosis. AD biomarkers in CSF are being intensively in-
vestigated [21]. At present, elevated CSF total, or phos-
phorylated tau proteins and low CSF-Aβ1−42 are the
only biomarkers with enough sensitivity and specificity
to serve as useful diagnostic biomarkers for identify-
ing AD in the early stages [17,45]. In agreement with
the largest study published to date [45], we established
the ratio total tau/Aβ1−42 achieved in women with a
sensitivity of 87% and a specificity of 92% when dif-
ferentiating PMCI and mild-AD from SCI and SMCI.
Interestingly, when insulin was combined with the total
tau/Aβ1−42 ratio, the sensitivity increased to 100% and
the specificity accuracy to 95%. The enhanced predic-
tion accuracy might be attributed to the lack of corre-
lation between CSF-insulin and CSF-Aβ1−42, or tau.
Statistically, when two markers are not correlated, the
increase in prediction accuracy is incremental. The ap-
pearance of such striking improvement in AD diagnosis
in women from the PMCI group suggests that, just by
adding simple, well implemented and inexpensive in-
sulin measurements to the classical AD CSF biomark-
ers, one could diagnose AD in females, at least, two
years earlier. Confirmatory studies using larger sam-
ples are essential to establish the clinical significance
of this finding.
In summary, the present study presents evidence that
insulin levels are reduced in AD brains. This reduction
is first seen in women at early stages of the disease.
Overall, our findings support the role of brain insulin
dysfunction as an early event in AD pathophysiology,
and suggest that by CSF-insulin could improve early
diagnosis of AD in females.
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